PURPOSE Black Americans with hypertension have poorer blood pressure control than their white counterparts, but the impact of this disparity on mortality among black adults is not known. We assessed differences in systolic blood pressure (SBP) control among white and black adults with a diagnosis of hypertension, and measured the impact of that difference on cardiovascular and cerebrovascular mortality among blacks.
INTRODUCTION
C ardiovascular disease, the leading cause of death in the United States, occurs at the highest rate among black Americans. 1 As a precursor to cardiovascular disease, hypertension is one of the most important contributors to racial disparities in mortality rate. 2 The age-adjusted prevalence of hypertension is signifi cantly higher among blacks (39%) than among whites (29%). 3 Uncontrolled hypertension has an enormous impact on the health of minorities, 1, 4 accounting for up to one-quarter of all deaths among black adults, primarily from cardiovascular and cerebrovascular causes. 5 Recent data suggest that among persons under treatment for hypertension, blacks have poorer blood pressure control. 3 Only a few studies have quantifi ed the effects of racial disparities in health care interventions on the number of deaths among. 6, 7 To our knowledge, none have quantifi ed the impact of disparity in hypertension control on black mortality.
To model the impact of this disparity in hypertension control, we used national data on systolic blood pressure (SBP), mortality data, and published estimates of the relative risk associated with decreases in SBP. Specifi cally, we calculated the annual numbers of heart and stroke deaths R ACIA L DISPA RIT Y IN HY PERT ENSION CONT ROL that would be avoided or postponed assuming blacks with hypertension had their blood pressure controlled to the same level as whites.
METHODS

Data Sources
We used SBP data from the National Health and Nutrition Examination Survey (NHANES) for the years 1999-2002. NHANES is a periodic national survey of the health status of the United States and is designed to yield nationally representative estimates. It includes data from questionnaires, physical examinations, and medical tests. Eligibility criteria for our sample included (1) self-identifi cation as white or black, (2) age of 25 years or older, and (3) diagnosis of hypertension (regardless if treated or not). We also used 2002 US black mortality data for heart disease and stroke, stratifi ed by sex and age. 8 We estimated the additional risk associated with an elevated SBP based on a meta-analysis of epidemiologic studies of SBP and mortality. This meta-analysis, based on approximately 1 million individuals, estimated the risks, stratifi ed by age and sex, of heart disease and stroke associated with elevated blood pressure. 9 We estimated the effect of reductions in SBP based on relative risks for heart disease and stroke mortality from a meta-analysis of randomized treatment trials of hypertension.
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Estimating Black Mortality Risk From Hypertension National mortality rates are known for all black adults (ie, those with and without hypertension), but not for black adults with hypertension. To estimate sex-and age-specifi c mortality rates for this group, we used NHANES data to derive the mean difference in SBP between blacks with hypertension and all blacks by sex and age. Next, we calculated the relative risk associated with a given difference in SBP between blacks with hypertension and all blacks using the following sex-and age-specifi c exponential function, derived from a meta-analysis of observational studies of blood pressure and mortality 9 :
where ΔSBP equals the difference in mean SBP between blacks with a hypertension diagnosis and all blacks aged 25 years or older, and RRs equals the relative risk for heart disease or stroke by age and sex for a standardized ΔSBP of 20 mm Hg. The relative risk was then applied to each sex and age category for heart disease and stroke mortality to produce mortality rates adjusted for hypertension. For example, the difference in mean SBP among black men aged 55 to 64 years with hypertension relative to all black men in this age category was 5 mm Hg (142 vs 137 mm Hg). This difference represents a relative risk for heart disease mortality of 1.17 (1/0.53 (5/20) ). The overall mortality rate for black men in this age-group is 605 deaths per 100,000. Among black men of this age with hypertension, the overall mortality is thus estimated at 708 per 100,000 (605 × 1.17). This estimate is conservative because it does not adjust for comorbidity (such as diabetes, hyperlipidemia, or obesity) associated with hypertension.
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Estimating Relative Risk From Disparity in SBP We estimated the relative risk associated with racial disparity in SBP based on a reduction in the mean SBP for blacks to that of whites in the same sex and age group. We calculated the mean difference in SBP between blacks and whites for each group using NHANES data and used a relative risk for reduction in SBP from a meta-analysis of randomized trials of hypertension treatment. 10 In that meta-analysis, an 8.3-mm Hg reduction in SBP was associated with a relative risk of 0.80 (95% confi dence interval [CI], 0.77-0.84) for heart disease mortality and a relative risk of 0.67 (95% CI, 0.61-0.74) for stroke mortality. We then estimated the relative risk in heart disease mortality for various reductions in SBP using the following formula:
where ΔSBP equals the difference in SBP between blacks and whites matched for sex and age based on NHANES data, and RR s is the relative risk for heart disease or stroke standardized to an 8.3-mm Hg decrease in SBP. We then converted relative risks to relative risk reductions (RRR = 1 -RR).
Estimating Deaths From Disparity in SBP
To estimate the number of deaths among blacks that would be postponed or avoided if parity in SBP control were achieved, we multiplied the relative risk reduction by the sex-and age-specifi c mortality rates (AMR) for blacks adjusted for SBP to obtain the absolute risk reduction. We then multiplied this by the estimated number of blacks (N) in each sex and age group, derived from NHANES data. Our estimate for deaths was thus equal to RRR × AMR × N.
Statistical Analyses
The number of persons in each sex and age group and mean SBPs for blacks and whites were derived from NHANES data, weighted to yield national estimates R ACIA L DISPA RIT Y IN HY PERT ENSION CONT ROL using SAS (SAS Institute Inc, Cary, North Carolina). All other calculations were performed using Microsoft Excel (Microsoft Corp, Redmond, Washington).
Sensitivity Analyses
We conducted a series of sensitivity analyses around key estimates in the model. First, we assessed the effect of assuming a ±30% black-white difference in SBP. We also assumed a constant difference in SBP across all age-groups using the mean SBP by sex to assess the effect of age distributions on our fi ndings. Next, we used the 95% CIs surrounding the estimated relatives risks associated with decreases in SBP. 10 Last, we assumed comparable risk per change in SBP regardless of the source of the estimate, for example, observational data vs treatment data.
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RESULTS
There were 661 black adults and 1,335 white adults with hypertension in the sample and an additional 884 blacks without hypertension. Table 1 shows the number of black men and women in the sample with hypertension in each age-group along with their mean SBP and corresponding 95% CIs. For men, the mean SBP was 22 mm Hg higher in the oldest as compared with the youngest cohort. For women, that difference was 26 mm Hg.
The differences in mean SBP by age and sex among blacks with hypertension, the entire black adult population, and non-Hispanic whites with hypertension are shown in Table 2 . The mean SBP among black men with hypertension was 6 mm Hg higher than that for all black men and 6.5 mm Hg higher than that for white men with hypertension. For women, the differences were 6.5 and 8.2 mm Hg, respectively. Table 3 shows the annual mortality rates by age and sex for heart disease and stroke for the entire black population, estimates of annual mortality rates for those with hypertension, and estimates for blacks with hypertension assuming racial parity in blood pressure control. Parity in SBP control would reduce annual mortality rates from heart disease and stroke among men by 17% and 16%, respectively. For women, the reductions would be smaller, 9% and 14%, respectively.
Racial parity in hypertension control would reduce the annual number of deaths from heart disease and stroke by an estimated 5,480 and 2,190 (Table 4) . Sensitivity analyses are shown in the Supplemental Appendix (available online at http://www.annfammed. org/cgi/content/full/6/6/497/DC1). Use of 30% lower or higher estimates for racial differences in SBP yielded a 23% to 28% variation in death estimates. Use of a constant (mean SBP difference by race) across age-groups yielded slightly lower estimates for men, but substantially higher estimates for women relative to the base case. In general, use of a constant difference in SBP increased the number of deaths from heart disease by 43% and that from stroke by 49%. Use of the 95% upper and lower CIs yielded roughly 8% to 15% variations in estimates for heart disease deaths and 18% to 22% variations in those for stroke deaths. Last, substitution of age-and sex-specifi c relative risk values from observational studies for those from treatment studies yielded a 9% higher estimate of deaths from heart disease and a 21% lower estimate of deaths from stroke relative to the base case, but very similar estimates of death from heart disease and stroke combined (7,670 vs 7,720).
DISCUSSION
Our fi ndings show that racial disparity in SBP control contributes to nearly 8,000 excess deaths annually from heart disease and stroke among blacks. These fi ndings are fairly robust to changes in key model assumptions. Previous analyses have shown that hypertension is the single largest contributor, of any medical condition, to racial disparity in adult mortality. 2 This excess mortality results from a combination of a higher age-adjusted prevalence of hypertension and poorer control of blood pressure among those under treatment. 3 Our analysis estimated the contribution of just the latter factor to deaths among blacks, but nonetheless, found a substantial impact on the number of deaths in this racial group.
To our knowledge, this study represents the fi rst effort to quantify the toll of racial disparities in blood pressure control. Given the high prevalence of hypertension in blacks, appreciable benefi ts of blood pressure reduction, and signifi cant disparity in control, it is not surprising that disparity in blood pressure control results in appreciably more deaths than those estimated from other health care disparities, including infl uenza vaccination, mammography screening, use of β-blockers after myocardial infarction, treatment of childhood asthma, and diabetes. 6, 7 The causes of racial disparity in blood pressure control are not known. 12 There are several potential explanations-differences in access to care, clinician management, hypertension severity, and patient adherence. Surprisingly, NHANES data show no racial difference in treatment among all patients with hypertension, suggesting that rates of diagnosis and treatment among blacks in this sample are the same as among whites. 3 Although there is considerable evidence for racial disparity in management of cardiovascular disease, 13 there is little evidence of racial disparity in treatment of hypertension. Specifi cally, among those with hypertension, there is no signifi cant difference in rates of drug treatment of hypertension by race. 12 In addition, some data suggest no difference in clinician adherence to national hypertension treatment guidelines or intensifi cation of antihypertensive treatment by race. 14 It is possible that blacks have more severe hypertension or respond less favorably to antihypertensive drugs. There is no clear evidence, however, for racial differences in severity, and meta-analyses of treatment trials show a similar response to antihypertensive medication by race, with whites having a slightly greater response to β-blockers and blacks having a slightly greater response to diuretics. 15 There is evidence for racial disparity in patient adherence to antihypertensive medication, including studies conducted within the Veterans Administration Health System, where fewer differences in access appear to exist. [16] [17] [18] Differences in adherence by race may be due to affordability of medicines, personal beliefs, anticipated adverse effects, and health literacy that disproportionately affect blacks. [18] [19] [20] Although multiple causes may contribute to racial disparity in blood pressure control, this disparity is not inevitable. Disparity in hypertension control is signifi cantly smaller in the Veterans Administration Health System, where access barriers are fewer. 21 Little or no disparity in blood pressure control was noted in the treatment arms of 2 large community-based hypertension treatment trials, the Hypertension Detection and Follow-up Program and the Multiple Risk Factor Intervention Trial. 22, 23 It is thus probable that elimination of racial disparity in SBP is an attainable goal, provided suffi cient resources are available to discover and address adherence barriers.
The strengths of this study include use of a nationally representative sample to estimate blood pressures among persons with hypertension; use of race-, sex-, and age-specifi c national mortality rates for heart disease and stroke; and estimates of relative risk associated with SBP derived from meta-analyses.
The limitations of our study merit comment. The sample of hypertensive blacks, although derived from a nationally representative sample, was relatively small. CIs surrounding estimates of blood pressure for specifi c groups were therefore relatively wide. Because the number of deaths rises exponentially with age, even small variation in estimates of racial disparity in blood pressure among the elderly blacks can yield appreciable changes in estimates. This phenomenon is best illustrated by the results for women. Despite a higher black-white disparity in SBP, our fi ndings showed that elimination of this disparity would reduce deaths more among black men than among black women because the disparity for women is skewed toward younger ages. It is for this reason that use of a constant SBP yielded much higher estimates for women than men. In addition, because of small subgroup sizes, we used an upper age category of 75 years or older. Mean life expectancy at birth in 2004 was 69.5 years for black men and 75.3 years for black women. 1 Use of this cutoff underestimates the impact of these disparities on deaths among elderly black women. For these reasons, fi ndings that racial disparity in SBP disproportionately affects male mortality should be viewed with caution pending more precise estimates of racial disparity in blood pressure control among men and women of advanced age.
These caveats notwithstanding, our fi ndings suggest that racial disparity in hypertension control contributes appreciably to deaths among blacks from heart disease and stroke. Our analyses highlight the need to more fully understand the causes of these disparities and develop viable strategies to eliminate them, particularly clinician attention to adherence barriers among patients.
